ALK's sublingual tablet Odactra has been launched as a treatment for adult patients, ages 18 to 65 years, who have house dust mite-induced allergic rhinitis, with or without conjunctivitis.
ALK launches house dust mite-induced allergic rhinitis drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.